In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season.

On Aug. 22, the U.S. Food and Drug Administration announced the approval of a new Novavax COVID vaccine, as well as updated versions of the Pfizer-BioNTech and Moderna vaccines. According to NPR, this latest vaccine is already being distributed and administered across the country.

After years of long lines and occasional shortages, more Americans are opting not to get the updated COVID-19 vaccine this year, according to a new national survey.

Health data show that COVID-19 still surpasses all other infectious respiratory illnesses as a cause of severe illness, hospitalization and, sadly, death. The good news is that the margin between COVID-19 and influenza is the slimmest it has ever been.

The newly updated COVID-19 vaccine just arrived in pharmacies and clinics nationwide, and a new poll suggests nearly half of people age 50 and older plan to get it. But some older adults with high risk of severe illness appear unlikely to seek the vaccine,

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.